HEALTH
Anthos' detailed mid-stage data back its anticoagulant, but can the drug succeed where Bayer's failed? – Endpoints News
- Anthos’ detailed mid-stage data back its anticoagulant, but can the drug succeed where Bayer’s failed? Endpoints News
- Anthos spells out benefits of abelacimab in quest for safer blood thinners FirstWord Pharma
- Anti-clotting drug significantly reduces bleeding events in patients with atrial fibrillation, clinical trial shows Medical Xpress
- Study reveals abelacimab’s potential to improve anticoagulation safety for AFib patients News-Medical.Net
- Data Published Today in the New England Journal of Medicine GlobeNewswire
Source link
